WILMINGTON, Del. --(BUSINESS WIRE)--Jul. 8, 2026-- Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q2
Acquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease (VWD), strengthening Incyte’s late-stage pipeline WILMINGTON, Del. --(BUSINESS WIRE)--Jul. 6, 2026-- Incyte (Nasdaq:INCY) announced today it has completed its
If approved, Opzelura ® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failed AD, the most common type of eczema which affects 230 million people
WILMINGTON, Del. --(BUSINESS WIRE)--Jun. 19, 2026-- Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi ® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large
- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP - U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for zilurgisertib
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinib In essential thrombocythemia (ET), 87% of patients achieved a
- frontMIND study evaluating tafasitamab (Monjuvi ® /Minjuvi ®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and
- Proposed acquisition to add VGA039, a novel investigational monoclonal antibody that targets Protein S in Phase 3 development for von Willebrand disease (VWD) - Star Therapeutics to receive $1.25 billion upfront, with up to $750 million in additional payments upon achievement of sales milestones
- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP) FOSTER CITY, Calif. & WILMINGTON, Del. --(BUSINESS WIRE)--Jun. 4, 2026-- Mirum Pharmaceuticals, Inc.
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi ® /Minjuvi ®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)
WILMINGTON, Del. --(BUSINESS WIRE)--May 26, 2026-- Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 47 th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT. The presentation will be webcast live and can be accessed at Investor.Incyte.com and
The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data Incyte data will be securely used to train Genesis’ next-generation GEMS AI platform as part of Incyte’s efforts to speed up drug
WILMINGTON, Del. & SAN FRANCISCO --(BUSINESS WIRE)--May 19, 2026-- Incyte (Nasdaq:INCY) and Edison Scientific today announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for Incyte’s discovery and development work. This press release features multimedia.
Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi ® /Minjuvi ®) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts Session Oral and poster presentations to feature new data for INCA033989, an anti-mutant calreticulin
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) at the 2026 EADV Symposium The vast majority of
WILMINGTON, Del. --(BUSINESS WIRE)--May 6, 2026-- Incyte Corporation (Nasdaq:INCY) announced today that it granted equity inducement awards to Suketu (Suky) Upadhyay, the Company’s new Executive Vice President and Chief Financial Officer, pursuant to the Company’s 2024 Inducement Stock Incentive
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi ® (ruxolitinib) Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily Jakafi Jakafi XR will be available for pharmacy orders by May 8 WILMINGTON, Del.
WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 29, 2026-- Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: BofA Securities 2026 Health Care Conference on Wednesday, May 13, 2026 at 1:40 pm (PDT) and RBC 2026 Global Healthcare
Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi ® (ruxolitinib) net sales of $758 million, an increase of 7% compared to the same period in 2025 Opzelura ®
WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 28, 2026-- Incyte (Nasdaq:INCY) announces the appointment of Suketu (Suky) Upadhyay as Executive Vice President and Chief Financial Officer (CFO) effective May 4, 2026. In his new role, Mr. Upadhyay will serve as a key member of the Executive Leadership Team
- Data from pivotal frontMIND study of tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) featured in oral presentation at ASCO; results support global regulatory submissions WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 21, 2026-- Incyte (Nasdaq:INCY) today announced
WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 9, 2026-- Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q1
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1
WILMINGTON, Del. --(BUSINESS WIRE)--Mar. 25, 2026-- Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura ®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo WILMINGTON, Del.